First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.

CONCLUSION: The sole route of administration (i.e. oral versus injectable) was not a significant predictor of persistence with first-line DMDs in RRMS. PMID: 29526118 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29526118?dopt=Abstract

Source: Current Medical Research and Opinion - March 13, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research